Steve Slilaty - Sunshine Biopharma Chairman, CEO and Pres
| SBFM Stock | USD 2.44 0.08 3.39% |
Chairman
Dr. Steve N. Slilaty serves as a Chairman of the Board, President, Chief Executive Officer of Sunshine Biopharma, Inc., since October 15, 2009. In addition, since February 2002, Dr. Slilaty was President and Chief Scientific Officer of Advanomics Corporationrationration, Montreal, Canada, a privately held company engaged in the research, development and commercialization of drugs for the treatment of various forms of cancer. Advanomics Corporation is the third in a line of biotechnology companies that Dr. Slilaty founded and managed through their early and midstages of development. The first, Quantum Biotechnologies Inc. later known as Qbiogene Inc., was founded in 1991 and grew to over 60 million in annual sales. Today, Qbiogene is a member of a family of companies owned by MP Biomedicals, one of the international suppliers of biotechnology reagents with a catalogue containing over 55, 000 products. The second company which Dr. Slilaty founded, Genomics One Corporationrationration, now known as Alert BC Corporationrationration, conducted an initial public offering of its capital stock in 1999 and, on the basis of its ownership of Dr. Slilatys patented TrueBlue Technology, Genomics One became one of the handful of participants in the Human Genome Project. Formerly a research team leader of the Biotechnology Research Institute, a division of the National Research Council of Canada, Dr. Slilaty also served as a consultant in a management and advisory capacity for a Canadian biotechnology company between 1995 and 1997 during which time the company completed one of the biotechnology IPOs in Canada raising over 34 million since 2009.
| Age | 72 |
| Tenure | 15 years |
| Professional Marks | Ph.D |
| Address | 333 Las Olas Way, Fort Lauderdale, FL, United States, 33301 |
| Phone | 954-515-0810 |
| Web | https://sunshinebiopharma.com |
Steve Slilaty Latest Insider Activity
Tracking and analyzing the buying and selling activities of Steve Slilaty against Sunshine Biopharma stock is an integral part of due diligence when investing in Sunshine Biopharma. Steve Slilaty insider activity provides valuable insight into whether Sunshine Biopharma is net buyers or sellers over its current business cycle. Note, Sunshine Biopharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Sunshine Biopharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Steve Slilaty over three months ago Acquisition by Steve Slilaty of 1100000 shares of Sunshine Biopharma at 0.001 subject to Rule 16b-3 | ||
Steve Slilaty over six months ago Acquisition by Steve Slilaty of 321305416 shares of Sunshine Biopharma at 0.0026 subject to Rule 16b-3 | ||
Steve Slilaty over six months ago Discretionary transaction by Steve Slilaty of 17000000 shares of Sunshine Biopharma subject to Rule 16b-3 | ||
Steve Slilaty over a year ago Acquisition or disposition of Sunshine Biopharma securities by Steve Slilaty |
Sunshine Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.1075) % which means that it has lost $0.1075 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1798) %, meaning that it created substantial loss on money invested by shareholders. Sunshine Biopharma's management efficiency ratios could be used to measure how well Sunshine Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.18. In addition to that, Return On Capital Employed is likely to grow to -0.21. At this time, Sunshine Biopharma's Debt To Assets are very stable compared to the past year. As of the 26th of November 2024, Fixed Asset Turnover is likely to grow to 24.98, though Non Currrent Assets Other are likely to grow to (1.7 M).Similar Executives
| Found 1 records | CHAIRMAN Age | ||
| Andrew MD | Eliem Therapeutics | 47 | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.11 |
Sunshine Biopharma Leadership Team
Elected by the shareholders, the Sunshine Biopharma's board of directors comprises two types of representatives: Sunshine Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sunshine. The board's role is to monitor Sunshine Biopharma's management team and ensure that shareholders' interests are well served. Sunshine Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sunshine Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Abderrazzak Merzouki, COO and Director | ||
| Camille Sebaaly, CFO, Principal Accounting Officer, Secretary and Director | ||
| Steve Slilaty, Chairman, CEO and Pres | ||
| Robert Ferreira, President Inc | ||
| Malek Chamoun, Chief Officer | ||
| Marc Beaudoin, Chief Officer |
Sunshine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sunshine Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | (0.13) % | ||||
| Current Valuation | (6.92 M) | ||||
| Shares Outstanding | 2 M | ||||
| Shares Owned By Insiders | 0.23 % | ||||
| Shares Owned By Institutions | 1.84 % | ||||
| Number Of Shares Shorted | 374.13 K | ||||
| Price To Earning | 1.07 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share 197.42 | Quarterly Revenue Growth 0.416 | Return On Assets (0.11) | Return On Equity (0.18) |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.